Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Lysine-Proline-Valine
KPV is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the anti-inflammatory properties of the parent molecule in a smaller, more stable form.
KPV enters cells and inhibits NF-kB activation, reducing the production of pro-inflammatory cytokines. It has also shown antimicrobial activity and potential benefits for gut inflammation.
Preclinical studies demonstrate significant anti-inflammatory effects in models of colitis, dermatitis, and systemic inflammation. Oral KPV has shown efficacy in reducing intestinal inflammation in IBD models. Human clinical data is limited but promising for inflammatory bowel conditions.
Typical Dose
500mcg
Range
200-1000mcg
Frequency
1x/day (subcutaneous or oral)
Route
Oral, SubQ, or Topical
Duration
4-8 weeks
Reconstitution
5mg vial + 2mL bacteriostatic water = 2,500mcg/mL
Notes
Oral dosing targets gut inflammation directly. SubQ injection for systemic anti-inflammatory effects. Topical for localized skin conditions. Often cycled 4–8 weeks.
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
Build a protocol with KPV, schedule blood work for key biomarkers, and track your results.
Build Protocol with KPVThis platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs